PATENT CLAIM ANALYSIS

Application Number: 16101882
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["514", "375000"]

Abstract:
It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

Claim (Index 16):
The method of  claim 14 , wherein the disruption of TTR amyloid fibrils comprises increasing the amount of soluble protein (particles around 10 nm diameter) and decreasing the amount of aggregates fibrils with diameters of about 1,000 nm or higher.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 96.0
- Lexical Diversity: 1.83333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14353459', '15448054', '15736826', '13830731', '15480139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8053732179440724
- 35 USC 102 Novelty (BERT): 0.619445975784745
- Combined Prediction Score: 0.7867804937281396
- Mean Citation Score: 485.68719
- Max Citation Score: 735.84143
- Similarity Product: 466.4507060544061

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test